Literature DB >> 15223867

Development and validation of a short questionnaire in community acquired pneumonia.

R El Moussaoui1, B C Opmeer, P M M Bossuyt, P Speelman, C A J M de Borgie, J M Prins.   

Abstract

BACKGROUND: A short but sensitive questionnaire evaluating changes in respiratory symptoms and well being during the treatment of community acquired pneumonia (CAP) is needed. We have developed a measurement and evaluated its psychometric properties in 67 patients admitted with CAP.
METHODS: The patients were asked to indicate the presence and severity of dyspnoea, coughing, coughing up sputum, coughing up sputum with ease, the colour of the sputum, fatigue, fitness, and their state of health. The item fatigue showed substantial overlap with fitness and was therefore excluded. The response of the patients to the remaining eight items was used to calculate a CAP score.
RESULTS: The percentage of missing data (0.2-1.7%), floor and ceiling effects (0.2/5.5%), internal consistency (Cronbach alpha = 0.87), and the intraclass correlation coefficient for test-retest reproducibility (0.83) met predefined criteria, indicating good acceptability and reliability. Face and clinical validity were satisfactory. Effect sizes under treatment were large, indicating high responsiveness.
CONCLUSION: The newly developed CAP score is a simple, reliable, valid, and highly responsive instrument. This makes it scientifically sound and clinically relevant for measuring outcome when evaluating treatment strategies in CAP.

Entities:  

Mesh:

Year:  2004        PMID: 15223867      PMCID: PMC1747065          DOI: 10.1136/thx.2003.015107

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Measuring symptomatic and functional recovery in patients with community-acquired pneumonia.

Authors:  J P Metlay; M J Fine; R Schulz; T J Marrie; C M Coley; W N Kapoor; D E Singer
Journal:  J Gen Intern Med       Date:  1997-07       Impact factor: 5.128

2.  Influence of age on symptoms at presentation in patients with community-acquired pneumonia.

Authors:  J P Metlay; R Schulz; Y H Li; D E Singer; T J Marrie; C M Coley; L J Hough; D S Obrosky; W N Kapoor; M J Fine
Journal:  Arch Intern Med       Date:  1997-07-14

3.  Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.

Authors:  P P Gleason; W N Kapoor; R A Stone; J R Lave; D S Obrosky; R Schulz; D E Singer; C M Coley; T J Marrie; M J Fine
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

4.  Evaluating quality-of-life and health status instruments: development of scientific review criteria.

Authors:  K N Lohr; N K Aaronson; J Alonso; M A Burnam; D L Patrick; E B Perrin; J S Roberts
Journal:  Clin Ther       Date:  1996 Sep-Oct       Impact factor: 3.393

5.  The cost of treating community-acquired pneumonia.

Authors:  M S Niederman; J S McCombs; A N Unger; A Kumar; R Popovian
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

6.  A prediction rule to identify low-risk patients with community-acquired pneumonia.

Authors:  M J Fine; T E Auble; D M Yealy; B H Hanusa; L A Weissfeld; D E Singer; C M Coley; T J Marrie; W N Kapoor
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

7.  Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals.

Authors:  W C Holmes; J A Shea
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

8.  Measuring components of children's health status.

Authors:  M Eisen; J E Ware; C A Donald; R H Brook
Journal:  Med Care       Date:  1979-09       Impact factor: 2.983

9.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.

Authors:  C A McHorney; J E Ware; J F Lu; C D Sherbourne
Journal:  Med Care       Date:  1994-01       Impact factor: 2.983

10.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

View more
  15 in total

1.  Long-Term Pulmonary Outcomes of a Feasibility Study of Inverse-Planned, Multibeam Intensity Modulated Radiation Therapy in Node-Positive Breast Cancer Patients Receiving Regional Nodal Irradiation.

Authors:  Alice Y Ho; Ase Ballangrud; Guang Li; Gaorav P Gupta; Beryl McCormick; Richard Gewanter; Daphna Gelblum; Melissa Zinovoy; Boris Mueller; Borys Mychalczak; Pinaki Dutta; Karen Borofsky; Preeti Parhar; Marsha Reyngold; Lior Z Braunstein; Mohit Chawla; Kate Krause; Natasha Freeman; Chun Ting Siu; Zachary Cost; Brittany B Arnold; Zhigang Zhang; Simon N Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

2.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.

Authors:  Rachida el Moussaoui; Corianne A J M de Borgie; Peterhans van den Broek; Willem N Hustinx; Paul Bresser; Guido E L van den Berk; Jan-Werner Poley; Bob van den Berg; Frans H Krouwels; Marc J M Bonten; Carla Weenink; Patrick M M Bossuyt; Peter Speelman; Brent C Opmeer; Jan M Prins
Journal:  BMJ       Date:  2006-06-10

Review 3.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

4.  Postdischarge Recovery after Acute Pediatric Lung Disease Can Be Quantified with Digital Biomarkers.

Authors:  Matthijs D Kruizinga; Allison Moll; Ahnjili Zhuparris; Dimitrios Ziagkos; Frederik E Stuurman; Marianne Nuijsink; Adam F Cohen; Gertjan J A Driessen
Journal:  Respiration       Date:  2021-05-18       Impact factor: 3.580

5.  A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days.

Authors:  Daniel G Wootton; Laura Dickinson; Henry Pertinez; Joanne Court; Odiri Eneje; Lynne Keogan; Laura Macfarlane; Sarah Wilks; Jane Gallagher; Mark Woodhead; Stephen B Gordon; Peter J Diggle
Journal:  Eur Respir J       Date:  2017-06-15       Impact factor: 16.671

6.  Patient-reported outcome measures in community-acquired pneumonia: a systematic review of application and content validity.

Authors:  Melanie Lloyd; Emily Callander; Amalia Karahalios; Lucy Desmond; Harin Karunajeewa
Journal:  BMJ Open Respir Res       Date:  2019-06-02

Review 7.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

8.  Pneumonia recovery: discrepancies in perspectives of the radiologist, physician and patient.

Authors:  Anke H W Bruns; Jan Jelrik Oosterheert; Rachida El Moussaoui; Brent C Opmeer; Andy I M Hoepelman; Jan M Prins
Journal:  J Gen Intern Med       Date:  2009-12-05       Impact factor: 5.128

9.  Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.

Authors:  Claudine A Blum; Nicole Nigro; Bettina Winzeler; Isabelle Suter-Widmer; Philipp Schuetz; Matthias Briel; Roland Bingisser; Werner Zimmerli; Elke Ullmer; Hanno Elsaesser; Philip Tarr; Sebastian Wirz; Robert Thomann; Eveline Hofmann; Nicolas Rodondi; Hervé Duplain; Dieter Burki; Beat Mueller; Mirjam Christ-Crain
Journal:  Trials       Date:  2014-06-28       Impact factor: 2.279

10.  Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population.

Authors:  Melanie A Lloyd; Clarice Y Tang; Emily J Callander; Edward D Janus; Amalia Karahalios; Elizabeth H Skinner; Stephanie Lowe; Harin A Karunajeewa
Journal:  Pilot Feasibility Stud       Date:  2019-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.